The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study

• DOI: 10.3389/fimmu.2023.1325462
• Publication Date: 2023-12-11T06:04:51Z
• Authors: Takashi Kurosaki; Kenji Chamoto; Shinichiro Suzuki; Hiroaki Kanemura; Seiichiro Mitani; Kaoru Tanaka; Hisato Kawakami; Yo Kishimoto; Yasuharu Haku; Katsuhiro Ito; Toshiyuki Sato; Chihiro Suminaka; Mami Yamaki; Yasutaka Chiba; Tomonori Yaguchi; Koichi Omori; Takashi Kobayashi; Kazuhiko Nakagawa; Tasuku Honjo; Hidetoshi Hayashi
• Keywords: Microsatellite Instability

Introduction The clinical relevance of soluble forms programmed cell death-1 (sPD-1) and death-ligand 1 (sPD-L1) remains unclear. We here investigated the relation between efficacy PD-1 blockade pretreatment plasma levels sPD-1 sPD-L1 across a broad range cancer types. Methods retrospectively analyzed data from 171 patients with advanced solid tumors who received nivolumab or pembrolizumab monotherapy regardless treatment line. concentrations were measured fully automated immunoassay (HISCL system). Results study subjects comprised head neck ( n = 50), urothelial 42), renal 37), gastric 20), esophageal 10), malignant pleural mesothelioma 6), microsatellite instability-high 6). High low not significantly associated progression-free survival (PFS) overall (OS) for in entire population. Comparison outcomes according to combinations high levels, however, revealed that had poorer PFS (HR 1.79 [95% CI, 1.13–2.83], p 0.01) tendency toward OS 1.70 0.99–2.91], 0.05) compared all other patients. Conclusion Our findings suggest combination is potential negative biomarker therapy.